Jennison Associates LLC Sells 1,777,236 Shares of Arcutis Biotherapeutics, Inc. $ARQT

Posted by Stanley Muller on Jul 19th, 2026

Jennison Associates LLC reduced its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 26.3% during the first quarter, Holdings Channel reports. The institutional investor owned 4,980,770 shares of the company’s stock after selling 1,777,236 shares during the period. Jennison Associates LLC’s holdings in Arcutis Biotherapeutics were worth $117,347,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ARQT. SBI Securities Co. Ltd. increased its holdings in shares of Arcutis Biotherapeutics by 325.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock valued at $32,000 after acquiring an additional 833 shares in the last quarter. Global Retirement Partners LLC bought a new position in shares of Arcutis Biotherapeutics in the 4th quarter worth $35,000. EverSource Wealth Advisors LLC grew its position in Arcutis Biotherapeutics by 124.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock valued at $37,000 after purchasing an additional 698 shares during the period. NewEdge Advisors LLC grew its position in Arcutis Biotherapeutics by 209.0% in the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock valued at $45,000 after purchasing an additional 1,045 shares during the period. Finally, Truvestments Capital LLC grew its position in Arcutis Biotherapeutics by 114.2% in the 4th quarter. Truvestments Capital LLC now owns 3,012 shares of the company’s stock valued at $87,000 after purchasing an additional 1,606 shares during the period.

Arcutis Biotherapeutics Stock Up 2.7%

ARQT stock opened at $28.49 on Friday. The firm has a market capitalization of $3.56 billion, a PE ratio of -949.35 and a beta of 1.48. The company has a quick ratio of 2.46, a current ratio of 2.68 and a debt-to-equity ratio of 0.54. Arcutis Biotherapeutics, Inc. has a twelve month low of $13.69 and a twelve month high of $31.77. The stock’s 50 day moving average is $24.17 and its 200-day moving average is $24.79.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.07). The company had revenue of $105.40 million for the quarter, compared to the consensus estimate of $103.67 million. Arcutis Biotherapeutics had a negative return on equity of 1.41% and a negative net margin of 0.57%. Sell-side analysts expect that Arcutis Biotherapeutics, Inc. will post 0.16 EPS for the current fiscal year.

Analysts Set New Price Targets

ARQT has been the topic of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a report on Wednesday, June 24th. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price objective on shares of Arcutis Biotherapeutics in a report on Thursday, May 7th. Finally, Wall Street Zen raised shares of Arcutis Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.00.

Get Our Latest Analysis on ARQT

Insider Activity

In other news, Director Sue-Jean Lin sold 4,946 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.38, for a total value of $120,583.48. Following the completion of the sale, the director owned 27,567 shares in the company, valued at $672,083.46. This represents a 15.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Howard G. Welgus sold 7,144 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $22.99, for a total transaction of $164,240.56. Following the transaction, the director directly owned 32,600 shares in the company, valued at $749,474. The trade was a 17.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 30,931 shares of company stock worth $730,086. Company insiders own 9.40% of the company’s stock.

Arcutis Biotherapeutics Profile

(Free Report)

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.